Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -81.20M | -80.58M | -74.00M | -66.54M | -12.82M |
| Total Depreciation and Amortization | 11.95M | 11.90M | 11.90M | 11.98M | 11.67M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.83M | 56.49M | 53.63M | 54.67M | 6.05M |
| Change in Net Operating Assets | 3.83M | 6.15M | 1.18M | -4.79M | -6.82M |
| Cash from Operations | -6.59M | -6.04M | -7.30M | -4.69M | -1.92M |
| Capital Expenditure | -6.89M | -6.04M | -5.40M | -4.08M | -3.98M |
| Sale of Property, Plant, and Equipment | 275.00K | 205.00K | 225.00K | 252.00K | 248.00K |
| Cash Acquisitions | -- | -- | -- | -- | -471.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.08M | 2.86M | -21.24M | 13.95M | -47.27M |
| Cash from Investing | -23.70M | -2.98M | -26.41M | 10.12M | -51.47M |
| Total Debt Issued | 7.59M | 8.62M | 9.96M | 5.58M | 6.95M |
| Total Debt Repaid | -7.79M | -5.57M | -4.10M | -4.75M | -1.94M |
| Issuance of Common Stock | 2.50M | 1.63M | 1.46M | 1.47M | 1.78M |
| Repurchase of Common Stock | -921.00K | -799.00K | -5.23M | -15.74M | -22.63M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.00K | 1.00K | 1.00K | 1.00K | -- |
| Cash from Financing | 1.38M | 3.88M | 2.09M | -13.43M | -15.85M |
| Foreign Exchange rate Adjustments | 2.82M | 3.51M | 1.98M | 109.00K | 215.00K |
| Miscellaneous Cash Flow Adjustments | -- | 2.00K | 1.00K | 1.00K | 1.00K |
| Net Change in Cash | -26.09M | -1.62M | -29.63M | -7.89M | -69.02M |